

Minutes of Pre-bid meeting held on 01/07/2013 at 14:00 hr at RITES office for Supply of ARV Drugs (ANTI RETRO-VIRAL DRUGS) (PAEDIATRIC) against: IFB No. RITES/MSM/NACP/03/2013

1. The following were present:-

I) From RITES

S/Shri

A Sharma, GGM/MSM– In Chair
P Mirani, GM/MSM
R K Sharma, Sr.DGM/MSM
M K Das, Manager/MSM
Anil Gupta, Pharmaceutical Expert/MSM

II) From NACO

Dr. Reshu Agarwal, PO/NACO

III) Firms which attended the pre bid conference are as follows:

| S. No. | Name of representative S/Shri | Name of Firm |
|--------|-------------------------------|--|
| 1. | Ravi Mehta | M/s Ranbaxy Laboratories Ltd., Gurgaon |
| | Sandeep Sarkar | |
| | Taher Karampurwala | |
| | Sumit Misra | |
| | J Ganesh | |
| 2. | S. Ranjit Singh | M/s Hetero Drugs Ltd., Hyderabad |
| 3. | Raja Mahesh | M/s Aurobindo Pharma Ltd., Hyderabad |
| | Arun Sharma | M/s Pharmimax India |
| 4. | Vijay Chauhan | M/s Emcure Pharmaceuticals Ltd., Pune |
| 5. | A K Rastogi | M/s Cipla Ltd., Mumbai |

2. Initiating the discussion, chairperson welcomed the participants. It was explained that purpose of Pre-bid meet is to educate the bidders regarding various important provisions of the bidding documents and also to clarify any queries that the bidders may have in the subject bidding documents.

3. The issues raised during the pre bid meeting and clarifications are as under-

| S. No. | Query Raised | Clarification |
|--------|---|--|
| | Section II: Bid Data Sheet | |
| 1. | M/s Aurobindo Pharma and M/s Hetero have advised that custom authorities will not entertain custom duty exemption certificate (CDEC) issued from NACO as GFATM has still not been included in the list of international donors. These bidders want a confirmation from NACO that in case custom authorities do not accept CDEC issued from NACO and they are forced to pay Custom Duty then the same would be reimbursed by NACO. (Refer ITB 16.2 (a) & | Custom Duty Exemption Certificate (CDEC) will be issued, if applicable. In case, the duty is paid, the same will be reimbursed by NACO (DAC) upon production of original documentary evidence. Please also refer Amendment No. 1. |

| S. No. | Query Raised | Clarification |
|--------|---|---|
| | <i>16.2 (b)(i) at page 45-46)</i> | |
| | Section VI: Schedule of Requirements | |
| | All the participants have requested to permit them to supply each Lot in two/three installments as quantities are very large. | Supply of each Lot in two installments is permitted. Please also refer Amendment No. 1. |
| | Section VII: Technical Specifications | |
| 2. | <p><i>(Refer Page 100 to 108)</i></p> <p>M/s Aurobindo Pharama has asked the following query:</p> <p>Refer point No.4 Primary Container: Suitable opaque plastic bottle contain 60 Tablets/capsules. Each Bottle duly sealed with plastic plug/diaphragm and should contain silicon packs. Tightly fitting suitable screw cap.</p> <p>APL Specification: This product packed into HDPE Container and duly sealed with pp screw cap with no silica gel packs. They have stability data for 24 months and found well within specification limits. Hence this product does not required silica gel packs to be put in container.</p> <p>In view of above, the firm has requested to amend the clause.</p> | This is as per DCGI guidelines and DAC faced some issues of broken tablets, which could be due to absence of silica gel, which probably absorbs any moisture. Therefore not agreed. |
| | VIII. Sample Forms | |
| 3. | It was requested by participants to remove Stock Ledger details from Final Acceptance Certificate (FAC) Form as consignees take time to fill such details and some consignees issue the FAC without such details causing problem at the time of release of payment. <i>(Refer Form 17 at Page 144)</i> | Suitable modification in Final Acceptance Certificate (FAC) Form has been done. Please Refer Amendment No. 1 for Modified Form 17. |

Meeting concluded with thanks to the participants for their active participation.